Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — 9th Annual SVB Leerink Global Healthcare Conference (February 2020)
11 slides from Ironwood Pharmaceuticals's conference presentation, Feb 25, 2020
Slide 1: SVB Leerink Global Healthcare Conference
SVB Leerink Global Healthcare Conference February 25, 2020 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision to become a leader in GI; our ability to execute on our strategy, incl
Slide 3: Executing on Our Strategy
Executing on Our Strategy Drive LINZESS® Advance late-stage Deliver (linaclotide) growth U.S. GI development sustainable profits portfolio 3
Slide 4: LINZESS is #1 Prescribed Medicine for IBS-C/CIC
LINZESS is #1 Prescribed Medicine for IBS-C/CIC Strong 2019 performance driven by double-digit demand growth1 IBS-C/CIC Prescription Category in US1 In 2020: 350,000 Expect mid-single digit % increase in U.S. 300,000 LACTULOSE net sales in 2020 250,000 Expect stabilized net price in 2020, while 200,
Slide 5: Advancement of late-stage GI pipeline
Advancement of late-stage GI pipeline Two important data milestones targeted in 2020 MD-7246 ✓ Phase II top-line data targeted mid-2020 ✓ Potential to be a non-opioid, intestinal, pain-relieving agent for treatment of abdominal pain associated with certain GI diseases ✓ Initially in development for
Slide 6: Full Year 2020 Financial Guidance
Full Year 2020 Financial Guidance Ironwood expects: FY2020 Guidance LINZESS U.S. net sales growth Mid-single digit % increase Total Ironwood revenue $360 – 380 million Adjusted EBITDA1 >$105 million 1. Adjusted EBITDA is calculated by subtracting net interest expense, taxes, depreciation, amortizati
Slide 7: Ironwood Positioned for Long-Term Growth and Value Creation
Ironwood Positioned for Long-Term Growth and Value Creation IW-3718 and MD-7246 represent significant commercial opportunities, if approved Total Ironwood Revenue8 ~10M IBS-C / CIC U.S. adults1 >$1 Billion U.S. net sales opportunity IW-3718 MD-7246 (if approved) ~8-10M rGERD U.S. adults2,3,4,5 + (if
Slide 8: Thank You!
Thank You ~ \ q ronwoo
Slide 9: 4Q and FY 2019 financial summary
4Q and FY 2019 financial summary Reconciliation of GAAP results to non-GAAP financial measures1 Three Months Ended Twelve Months Ended December 31, 2019 December 31, 2019 (000s, except per share (000s, except per share Reconciliation of GAAP Results to Non-GAAP Financial Measures amounts) amounts) G
Slide 10: 4Q and FY 2019 financial summary
4Q and FY 2019 financial summary Reconciliation of GAAP net income from continuing operations to adjusted EBITDA from continuing operations Three Months Ended Twelve Months Ended December 31, 2019 December 31, 2019 (000s, except per share amounts) (000s, except per share amounts) GAAP net income fro
Slide 11: 4Q and FY 2019 financial summary
4Q and FY 2019 financial summary LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Ironwood & Allergan Total Net Profit Twelve Months Twelve Months Three Months Ended Three Months Ended Ended Ended December 31, 2019 December 31, 2019 December 31, 2019 December 31, 2019 (000